Targeting NK-cell checkpoints for cancer immunotherapy

Aura Muntasell; Maria C. Ochoa; Luna Cordeiro; Pedro Berraondo; Ascension López-Díaz de Cerio; Mariona Cabo; Miguel López-Botet; Ignacio Melero

doi:10.1016/j.coi.2017.01.003

Targeting NK-cell checkpoints for cancer immunotherapy

Aura Muntasell, Maria C. Ochoa, Luna Cordeiro, Pedro Berraondo, Ascension López-Díaz de Cerio, Mariona Cabo, Miguel López-Botet, Ignacio Melero

Departament de Biologia Cel·lular, de Fisiologia i d'Immunologia

Producció científica: Contribució a revista › Article de revisió › Recerca › Avaluat per experts

166 Cites (Scopus)

Resum

Natural Killer (NK) cells are cytotoxic lymphocytes specialized in early defense against virus-infected and transformed cells. NK-cell function is regulated by activating and inhibitory surface receptors recognizing their ligands on transformed cells. Modulation of NK numbers and/or function by a variety of agents such as cytokines and monoclonal antibodies may result in enhanced anti-tumor activity. Recombinant cytokines (i.e., IL-15 and IL-2), antibodies blocking inhibitory receptors (i.e., KIR, NKG2A and TIGIT) and agonists delivering signals via CD137, NKG2D and CD16 stand out as the most suitable opportunities. These agents can be used to potentiate NKcell- mediated antibody-dependent cellular cytotoxicity (ADCC) against antibody-coated tumor cells, offering potential for multiple combinatorial immunotherapy strategies against cancer.

Idioma original	Anglès
Pàgines (de-a)	73-81
Nombre de pàgines	9
Revista	Current Opinion in Immunology
Volum	45
DOIs	https://doi.org/10.1016/j.coi.2017.01.003
Estat de la publicació	Publicada - 1 d’abr. 2017

SDG de les Nacions Unides

Aquest resultat contribueix als següents objectius de desenvolupament sostenible.

Accés al document

10.1016/j.coi.2017.01.003

Altres arxius i enllaços

Enllaç a la publicació de Scopus

Com citar-ho

@article{687543cedc3746758d0de51124f2f80c,

title = "Targeting NK-cell checkpoints for cancer immunotherapy",

abstract = "Natural Killer (NK) cells are cytotoxic lymphocytes specialized in early defense against virus-infected and transformed cells. NK-cell function is regulated by activating and inhibitory surface receptors recognizing their ligands on transformed cells. Modulation of NK numbers and/or function by a variety of agents such as cytokines and monoclonal antibodies may result in enhanced anti-tumor activity. Recombinant cytokines (i.e., IL-15 and IL-2), antibodies blocking inhibitory receptors (i.e., KIR, NKG2A and TIGIT) and agonists delivering signals via CD137, NKG2D and CD16 stand out as the most suitable opportunities. These agents can be used to potentiate NKcell- mediated antibody-dependent cellular cytotoxicity (ADCC) against antibody-coated tumor cells, offering potential for multiple combinatorial immunotherapy strategies against cancer.",

author = "Aura Muntasell and Ochoa, \{Maria C.\} and Luna Cordeiro and Pedro Berraondo and \{L{\'o}pez-D{\'i}az de Cerio\}, Ascension and Mariona Cabo and Miguel L{\'o}pez-Botet and Ignacio Melero",

note = "Publisher Copyright: {\textcopyright} 2017",

year = "2017",

month = apr,

day = "1",

doi = "10.1016/j.coi.2017.01.003",

language = "English",

volume = "45",

pages = "73--81",

journal = "Current Opinion in Immunology",

issn = "0952-7915",

publisher = "Elsevier Limited",

}

TY - JOUR

T1 - Targeting NK-cell checkpoints for cancer immunotherapy

AU - Muntasell, Aura

AU - Ochoa, Maria C.

AU - Cordeiro, Luna

AU - Berraondo, Pedro

AU - López-Díaz de Cerio, Ascension

AU - Cabo, Mariona

AU - López-Botet, Miguel

AU - Melero, Ignacio

PY - 2017/4/1

Y1 - 2017/4/1

N2 - Natural Killer (NK) cells are cytotoxic lymphocytes specialized in early defense against virus-infected and transformed cells. NK-cell function is regulated by activating and inhibitory surface receptors recognizing their ligands on transformed cells. Modulation of NK numbers and/or function by a variety of agents such as cytokines and monoclonal antibodies may result in enhanced anti-tumor activity. Recombinant cytokines (i.e., IL-15 and IL-2), antibodies blocking inhibitory receptors (i.e., KIR, NKG2A and TIGIT) and agonists delivering signals via CD137, NKG2D and CD16 stand out as the most suitable opportunities. These agents can be used to potentiate NKcell- mediated antibody-dependent cellular cytotoxicity (ADCC) against antibody-coated tumor cells, offering potential for multiple combinatorial immunotherapy strategies against cancer.

AB - Natural Killer (NK) cells are cytotoxic lymphocytes specialized in early defense against virus-infected and transformed cells. NK-cell function is regulated by activating and inhibitory surface receptors recognizing their ligands on transformed cells. Modulation of NK numbers and/or function by a variety of agents such as cytokines and monoclonal antibodies may result in enhanced anti-tumor activity. Recombinant cytokines (i.e., IL-15 and IL-2), antibodies blocking inhibitory receptors (i.e., KIR, NKG2A and TIGIT) and agonists delivering signals via CD137, NKG2D and CD16 stand out as the most suitable opportunities. These agents can be used to potentiate NKcell- mediated antibody-dependent cellular cytotoxicity (ADCC) against antibody-coated tumor cells, offering potential for multiple combinatorial immunotherapy strategies against cancer.

UR - https://www.scopus.com/pages/publications/85013459761

U2 - 10.1016/j.coi.2017.01.003

DO - 10.1016/j.coi.2017.01.003

M3 - Review article

C2 - 28236750

AN - SCOPUS:85013459761

SN - 0952-7915

VL - 45

SP - 73

EP - 81

JO - Current Opinion in Immunology

JF - Current Opinion in Immunology

ER -

Targeting NK-cell checkpoints for cancer immunotherapy

Resum

SDG de les Nacions Unides

Accés al document

Altres arxius i enllaços

Fingerprint

Com citar-ho